Baisley, K J Seeley, J Siedner, M J Koole, K Matthews, P Tanser, F Bärnighausen, T Smit, T Gareta, D Dlamini, S
...
Published in
HIV medicine
The aim of the study was to estimate rates of linkage to HIV care and antiretroviral treatment (ART) initiation after the introduction of home-based HIV counselling and testing (HBHCT) and telephone-facilitated support for linkage in rural South Africa. A population-based prospective cohort study was carried out in KwaZulu Natal, South Africa. All ...
Besutti, G Santoro, A Scaglioni, R Neri, S Zona, S Malagoli, A Orlando, G Beghè, B Ligabue, G Torricelli, P
...
Published in
HIV medicine
The aim of the study was to describe chronic lung disease in HIV-infected never-smokers by looking at clinical, structural and functional abnormalities. This comparative cross-sectional study included 159 HIV-infected never-smoking patients [mean (± standard deviation) age 54.6 ± 9.1 years; 13.2% female; 98.1% with undetectable viral load] and 75 n...
Alejos, B Stella-Ascariz, N Montejano, R Rodriguez-Centeno, J Schwimmer, C Bernardino, J I Rodes, B Esser, S Goujard, C Sarmento-Castro, R
...
Published in
HIV medicine
Our aim was to investigate factors associated with baseline blood telomere length in participants enrolled in NEAT 001/ANRS 143, a randomized, open-label trial comparing ritonavir-boosted darunavir (DRV/r) plus raltegravir (RAL) with DRV/r plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in antiretroviral therapy (ART)-naïve HIV-positive ...
Frange, P Avettand-Fenoel, V Veber, F Blanche, S
Published in
HIV medicine
The aim of the study was to carry out a comparison of the safety and efficacy of dolutegravir-based regimens among age groups of HIV-1-infected paediatric and young adult patients. This retrospective monocentric study included 109 patients infected since childhood who began receiving dolutegravir between January 2014 and December 2017. The patients...
Mendez-Lopez, A McKee, M Stuckler, D Granich, R Gupta, S Noori, T Semenza, J C
Published in
HIV medicine
Although the benefits of adopting test-and-treat antiretroviral therapy (ART) guidelines that recommend initiation of ART regardless of CD4 cell counts have been demonstrated at the individual level, there is uncertainty about how this translates to the population level. Here, we explored whether adopting ART guidelines recommending earlier treatme...
Brogan, A J Talbird, S E Davis, A E Wild, L Flanagan, D
Published in
HIV medicine
Early treatment of HIV-1 infection at all CD4 levels has demonstrated clinical and public health benefits. This analysis examined the costs, health outcomes, and cost-effectiveness of increased HIV-1 screening and early treatment initiation in the UK. A Markov model followed theoretical cohorts of men who have sex with men (MSM), heterosexuals, and...
Tadesse, B T Foster, A Aklillu, E
Published in
HIV medicine
Martin-Iguacel, R Pedersen, C Llibre, J M Søndergaard, J Jensen, J Omland, L H Johansen, I S Obel, N Rasmussen, L D
Published in
HIV medicine
We aimed to determine the fraction of HIV-diagnosed individuals who had primary health care (PHC) contacts 3 years prior to HIV diagnosis and whether the risk of HIV diagnosis and degree of immunodeficiency were associated with the frequency of visits or procedures performed. We used data from national registries to conduct a population-based neste...
Spinner, C D Lang, G F Boesecke, C Jessen, H Schewe, K
Published in
HIV medicine
HIV Pre-Exposure prophylaxis (PrEP) is a strategy to reduce HIV transmission in people at risk. Aim of this first German-Austrian PrEP guideline is to provide professional guidance on: when and in whom to use PrEP, recommended laboratory tests before and while on PrEP, selection of drugs, prevention of adverse events as a consequence of missing acc...
Fitzpatrick, C Lowe, M Richardson, D
Published in
HIV medicine
